Latest Replicel Life Sciences Inc (REPCF) Headlines
RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
Marketwire - Thu Feb 27, 7:05AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) announced that its Director of Research and Development, Dr. Hisae Nakamura, and its Chief Medical Officer, Dr. Kevin McElwee, will be presenting at the 13th Congress of the Japanese Society for Regenerative Medicine to be held March 4-6, 2014 in Kyoto, Japan. An oral presentation of Phase 1 clinical data for RCH-01 is scheduled for March 5, 2014 between 3-5 p.m. local time.
RepliCel Retains Ubika Communication for Online Capital Market Exposure
Marketwire - Wed Feb 26, 4:01PM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained Ubika Communication, a division of Ubika Corporation, to provide capital market exposure. Ubika offers capital market exposure services via their flagship website portal smallcapower.com (SCP) which is also featured on the Financial Post website. SCP represents a unique way for small cap companies to bridge between the traditional investor relations business model and the online world that is becoming increasingly important for maximizing shareholder value.
Androgenic Alopecia - Pipeline Review, H2 2013
M2 - Fri Feb 07, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/567n76/androgenic) has announced the addition of the "Androgenic Alopecia - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Androgenic Alopecia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Androgenic Alopecia. Androgenic Alopecia - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Androgenic Alopecia. - A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Androgenic Alopecia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Allergan - Histogen - Hygeia Therapeutics - Kasiak Research - Polichem - R-Tech Ueno - RepliCel Life Sciences - SWITCH Biotech - Samumed For more information visit http://www.researchandmarkets.com/research/567n76/androgenic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Eurasian Minerals Announces Royalty Interests on Timok Joint Venture Copper-Gold Properties in Serbia
Marketwire - Tue Feb 04, 6:01AM CST
Eurasian Minerals Inc. (TSX VENTURE: EMX)(NYSE MKT: EMXX) (the "Company" or "EMX") is pleased to announce the acquisition of an uncapped 0.5% net smelter return ("NSR") royalty covering Reservoir Minerals Inc.'s ("Reservoir" or "RMC") share of minerals and metals mined from the "Brestovac" and "Jasikovo East" properties in Serbia. These properties occur in the Timok Magmatic Complex, and are included in the Timok Project joint venture between Reservoir (45%) and Freeport-McMoRan Exploration Corp. ("Freeport") (55%). The Brestovac property hosts porphyry and epithermal copper-gold mineralization at the Cukaru Peki discovery, and the Jasikovo East property occurs to the north in the Timok copper-gold belt. Reservoir recently announced an initial NI 43-101 compliant resource estimate for the Cukaru Peki deposit. EMX congratulates Reservoir and Freeport on achieving this important milestone, as well as their continuing Timok Project exploration successes.
RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
Marketwire - Mon Jan 13, 7:02AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF) today announced that it has been granted a patent by Japan's Ministry of International Trade and Industry for hair follicle mesenchymal stem cells and their use thereof. These cells are used in RepliCel's RCH-01 treatment for androgenetic alopecia, also known as pattern hair loss. With the issuance of this patent, RepliCel now has patents issued in Japan, the United States, Australia and the European Union protecting its technology with other jurisdictions still pending.
CSE: 2014-0106-Delist-RepliCel Life Sciences Inc. (RP)
Marketwire - Thu Jan 09, 9:18AM CST
At the request of the Company, the common shares of RepliCel Life Sciences Inc. will be delisted at the market close Friday, January 10, 2014. RepliCel will continue to trade on the TSX Venture Exchange.
RepliCel to Commence Trading on the TSX Venture Exchange
Marketwire - Thu Jan 09, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP) is pleased to announce that its common shares are anticipated to commence trading on the TSX Venture Exchange (the "TSXV") on January 13, 2014 as a Tier 1 issuer. RepliCel will trade under its current trading symbol "RP". To ensure continued and seamless trading for RepliCel's shareholders, RepliCel's common shares will be delisted from the Canadian Securities Exchange at the close of trading on January 10, 2014 and will commence trading on the TSXV at market open on January 13, 2014.
RepliCel Life Sciences to Present at Biotech Showcase(TM) 2014
Marketwire - Thu Jan 09, 6:50AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP), a clinical stage biopharmaceutical company focused on developing therapies to address conditions associated with cellular deficits, today announced that CEO David Hall will present at the Biotech Showcase(TM) 2014 investor and partnering conference to be held January 13-15, 2014 in San Francisco, at the Parc 55 Wyndham Hotel. Mr. Hall will discuss RepliCel's autologous cell therapies for treating tendinosis and androgenetic alopecia at 2:30 p.m. PST on January 13, 2014. A copy of the presentation will be added to RepliCel's website and can be viewed here once posted.
Replicel Announces Conditional Approval from TSX Venture Exchange
Marketwire - Thu Jan 02, 7:01AM CST
RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCQB: REPCF) (CNSX: RP) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the "TSXV") for the listing of its common shares on the TSXV. The listing is subject to the Company fulfilling certain requirements of the TSXV in accordance with the terms of the conditional approval. Upon obtaining final approval, the Company will issue a further press release to update when it anticipates its common shares will commence trading on the TSXV. In connection with the Company's listing on the TSXV, the Company anticipates that 23,509,682 shares of its common stock (each, a "Share"), which represents approximately 49% of the Company's issued and outstanding shares, will be escrowed, with 25% of the escrowed Shares being released upon listing and a further 25% every six months. In addition, stock options to acquire upto1,400,000Shareswill also be subject to escrow under the same release schedule.
RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
Marketwire - Thu Dec 19, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP) today reported on the progress of its technology transfer agreement with its partner, Shiseido Company, Limited.
RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Nov 20, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today reported financial results for the third quarter and nine months ended September 30, 2013.
RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis
Marketwire - Wed Oct 30, 7:03AM CDT
RepliCel Life Sciences Inc. (OTCBB: REPCF)(CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies for regenerative medicine, today announced the formation of a clinical advisory board (CAB) to support the clinical development of its RCT-01 autologous cell therapy for the treatment of a variety of chronic tendon injuries including Achilles, patellar and elbow tendinosis. The board, chaired by Ross G. Davidson, MBChB, will provide its expertise and guidance on all aspects of the clinical trial program. Additional members include David A. Connell, MBBS, and Dr. Jack E. Taunton, M.D.
RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
Marketwire - Thu Feb 27, 7:05AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) announced that its Director of Research and Development, Dr. Hisae Nakamura, and its Chief Medical Officer, Dr. Kevin McElwee, will be presenting at the 13th Congress of the Japanese Society for Regenerative Medicine to be held March 4-6, 2014 in Kyoto, Japan. An oral presentation of Phase 1 clinical data for RCH-01 is scheduled for March 5, 2014 between 3-5 p.m. local time.
RepliCel Retains Ubika Communication for Online Capital Market Exposure
Marketwire - Wed Feb 26, 4:01PM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained Ubika Communication, a division of Ubika Corporation, to provide capital market exposure. Ubika offers capital market exposure services via their flagship website portal smallcapower.com (SCP) which is also featured on the Financial Post website. SCP represents a unique way for small cap companies to bridge between the traditional investor relations business model and the online world that is becoming increasingly important for maximizing shareholder value.
Androgenic Alopecia - Pipeline Review, H2 2013
M2 - Fri Feb 07, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/567n76/androgenic) has announced the addition of the "Androgenic Alopecia - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Androgenic Alopecia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Androgenic Alopecia. Androgenic Alopecia - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Androgenic Alopecia. - A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Androgenic Alopecia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Allergan - Histogen - Hygeia Therapeutics - Kasiak Research - Polichem - R-Tech Ueno - RepliCel Life Sciences - SWITCH Biotech - Samumed For more information visit http://www.researchandmarkets.com/research/567n76/androgenic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Eurasian Minerals Announces Royalty Interests on Timok Joint Venture Copper-Gold Properties in Serbia
Marketwire - Tue Feb 04, 6:01AM CST
Eurasian Minerals Inc. (TSX VENTURE: EMX)(NYSE MKT: EMXX) (the "Company" or "EMX") is pleased to announce the acquisition of an uncapped 0.5% net smelter return ("NSR") royalty covering Reservoir Minerals Inc.'s ("Reservoir" or "RMC") share of minerals and metals mined from the "Brestovac" and "Jasikovo East" properties in Serbia. These properties occur in the Timok Magmatic Complex, and are included in the Timok Project joint venture between Reservoir (45%) and Freeport-McMoRan Exploration Corp. ("Freeport") (55%). The Brestovac property hosts porphyry and epithermal copper-gold mineralization at the Cukaru Peki discovery, and the Jasikovo East property occurs to the north in the Timok copper-gold belt. Reservoir recently announced an initial NI 43-101 compliant resource estimate for the Cukaru Peki deposit. EMX congratulates Reservoir and Freeport on achieving this important milestone, as well as their continuing Timok Project exploration successes.
RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
Marketwire - Mon Jan 13, 7:02AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF) today announced that it has been granted a patent by Japan's Ministry of International Trade and Industry for hair follicle mesenchymal stem cells and their use thereof. These cells are used in RepliCel's RCH-01 treatment for androgenetic alopecia, also known as pattern hair loss. With the issuance of this patent, RepliCel now has patents issued in Japan, the United States, Australia and the European Union protecting its technology with other jurisdictions still pending.
CSE: 2014-0106-Delist-RepliCel Life Sciences Inc. (RP)
Marketwire - Thu Jan 09, 9:18AM CST
At the request of the Company, the common shares of RepliCel Life Sciences Inc. will be delisted at the market close Friday, January 10, 2014. RepliCel will continue to trade on the TSX Venture Exchange.
RepliCel to Commence Trading on the TSX Venture Exchange
Marketwire - Thu Jan 09, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP) is pleased to announce that its common shares are anticipated to commence trading on the TSX Venture Exchange (the "TSXV") on January 13, 2014 as a Tier 1 issuer. RepliCel will trade under its current trading symbol "RP". To ensure continued and seamless trading for RepliCel's shareholders, RepliCel's common shares will be delisted from the Canadian Securities Exchange at the close of trading on January 10, 2014 and will commence trading on the TSXV at market open on January 13, 2014.
RepliCel Life Sciences to Present at Biotech Showcase(TM) 2014
Marketwire - Thu Jan 09, 6:50AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP), a clinical stage biopharmaceutical company focused on developing therapies to address conditions associated with cellular deficits, today announced that CEO David Hall will present at the Biotech Showcase(TM) 2014 investor and partnering conference to be held January 13-15, 2014 in San Francisco, at the Parc 55 Wyndham Hotel. Mr. Hall will discuss RepliCel's autologous cell therapies for treating tendinosis and androgenetic alopecia at 2:30 p.m. PST on January 13, 2014. A copy of the presentation will be added to RepliCel's website and can be viewed here once posted.
Replicel Announces Conditional Approval from TSX Venture Exchange
Marketwire - Thu Jan 02, 7:01AM CST
RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCQB: REPCF) (CNSX: RP) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the "TSXV") for the listing of its common shares on the TSXV. The listing is subject to the Company fulfilling certain requirements of the TSXV in accordance with the terms of the conditional approval. Upon obtaining final approval, the Company will issue a further press release to update when it anticipates its common shares will commence trading on the TSXV. In connection with the Company's listing on the TSXV, the Company anticipates that 23,509,682 shares of its common stock (each, a "Share"), which represents approximately 49% of the Company's issued and outstanding shares, will be escrowed, with 25% of the escrowed Shares being released upon listing and a further 25% every six months. In addition, stock options to acquire upto1,400,000Shareswill also be subject to escrow under the same release schedule.
RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
Marketwire - Thu Dec 19, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP) today reported on the progress of its technology transfer agreement with its partner, Shiseido Company, Limited.
RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Nov 20, 7:02AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF)(CNSX: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today reported financial results for the third quarter and nine months ended September 30, 2013.
RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis
Marketwire - Wed Oct 30, 7:03AM CDT
RepliCel Life Sciences Inc. (OTCBB: REPCF)(CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies for regenerative medicine, today announced the formation of a clinical advisory board (CAB) to support the clinical development of its RCT-01 autologous cell therapy for the treatment of a variety of chronic tendon injuries including Achilles, patellar and elbow tendinosis. The board, chaired by Ross G. Davidson, MBChB, will provide its expertise and guidance on all aspects of the clinical trial program. Additional members include David A. Connell, MBBS, and Dr. Jack E. Taunton, M.D.
